This review evaluates how polyphenols target inflammation in obesity to inhibit cancer progression.
Obesity, a global epidemic, is increasingly recognized as a key risk factor for cancer development and progression. Central to this association is the state of chronic low-grade inflammation that characterizes obesity, which contributes to a pro-tumorigenic microenvironment. Adipose tissue dysfunction in obesity leads to elevated levels of inflammatory cytokines, immune cell infiltration, oxidative stress, and dysregulated adipokine secretion. These changes create a fertile ground for malignant transformation and cancer progression. Polyphenol-rich natural products, such as curcumin, resveratrol, quercetin, and epigallocatechin gallate (EGCG), exhibit potent anti-inflammatory, antioxidant, and anticancer properties. Emerging evidence from in vitro studies, animal models, and clinical trials suggests that these polyphenols can modulate obesity-induced inflammation and thereby inhibit cancer initiation and metastasis. This review highlights the mechanistic link between obesity, inflammation, and cancer, and evaluates the therapeutic potential of polyphenol-rich compounds in disrupting this axis. A deeper understanding of these natural products’ molecular mechanisms may pave the way for novel, safe, and effective strategies for cancer prevention and therapy, particularly in obese individuals.
No takes yet. Share an insight, caveat, or question.
Nassimbwa Kabanda D. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: